Hematologic Protection
Sustained neutrophil and platelet counts suggest trem-cel reduces the prolonged cytopenias historically associated with GO after standard alloHCT. The pharmacokinetic pattern after trem-cel suggests a potentially broader therapeutic index…
1 sources - 5 claims
Sustained neutrophil and platelet counts suggest trem-cel reduces the prolonged cytopenias historically associated with GO after standard alloHCT. The pharmacokinetic pattern after trem-cel suggests a potentially broader therapeutic index for GO. The intended mechanism is that GO depletes residual CD33-positive cells while sparing CD33-deleted donor hematopoiesis. At 2 mg/m2, GO produced measurable concentrations through the dosing interval without materially increasing peak concentration. Lower CD33 target density after CD33-deleted transplantation likely slowed GO clearance.